Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Scancell Holdings (SCLP) Share News

IN BRIEF: Scancell executive chair and co-founder both to depart

26th Oct 2022 14:30

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair. Read More

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

25th Oct 2022 12:17

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster. Read More

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

25th Oct 2022 10:44

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More

Scancell shares rocket on potentially lucrative Genmab licensing deal

25th Oct 2022 10:03

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab. Read More

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

16th Aug 2022 17:51

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform. Read More

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

23rd Jun 2022 21:28

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Scancell shares jump as phase 2 trial of skin cancer drug expands

15th Jun 2022 12:19

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval. Read More

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

13th Jun 2022 20:42

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Read More

LONDON MARKET MIDDAY: CAC moves green for Macron, FTSE 100 lags

11th Apr 2022 12:02

(Alliance News) - Stocks in Europe were having a mixed day on Monday, with the FTSE 100 feeling the weight of a poor UK GDP reading, but the CAC 40 in Paris gaining as investors in France show confidence in President Emmanuel Macron - as he looks set to extend his time in office. Read More

Scancell shares soar as clinical trial opens for recruitment

11th Apr 2022 11:17

(Alliance News) - Scancell Holdings PLC shares soared on Monday after the cancer immunotherapies developer said its phase 1/2 clinical trial with Modi-1 has opened for recruitment. Read More

IN BRIEF: Scancell broadens Covidity clinical trial in South Africa

29th Mar 2022 19:21

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Updates on South African Health Products Regulatory Authority's approval of a protocol amendment to the phase 1 Covidity clinical trial being conducted at the University of Cape Town Lung Institute in South Africa. Read More

TRADING UPDATES: SimiGon merger to go ahead; Segro launches green bond

17th Mar 2022 21:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Image Scan sinks as it expects to post significant loss in first half

22nd Feb 2022 11:50

(Alliance News) - Image Scan Holdings PLC shares tanked on Tuesday after the company said it expects to post a significant loss for the first half of financial 2022 and thinks it is "unlikely" that the second half will fully recover the loss. Read More

TRADING UPDATES: MJ Hudson and Tandem see results ahead of views

31st Jan 2022 22:07

TRADING UPDATES: MJ Hudson and Tandem see results ahead of views Read More

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit

26th Jan 2022 20:18

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit Read More

UK earnings, trading statements calendar - next 7 days

19th Jan 2022 16:02

UK earnings, trading statements calendar - next 7 days Read More

IN BRIEF: Scancell starts SCIB1 phase 2 trial in UK after pause

19th Nov 2021 11:37

IN BRIEF: Scancell starts SCIB1 phase 2 trial in UK after pause Read More

UK shareholder meetings calendar - next 7 days

16th Nov 2021 16:09

UK shareholder meetings calendar - next 7 days Read More

DIRECTOR DEALINGS: MD of Gleeson Homes buys GBP150,000 in shares

2nd Nov 2021 15:20

DIRECTOR DEALINGS: MD of Gleeson Homes buys GBP150,000 in shares Read More

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

1st Nov 2021 06:57

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors Read More

FTSE 100 Latest
Value8,275.66
Change0.00